DISCUSSION
NSCLC, toxicities, cancer
CANCER, NSCLC, SOLID TUMOR
The JMTO LC14‐01 phase II trial is the first randomized trial to evaluate optimal dose of nab‐PTX in previously treated patients with advanced NSCLC. Both 100 and 70 mg/mHigh‐dose medication is not always required to elicit clinical benefit. Indeed, greater efficacy at higher doses of chemotherapy was not observed in a solid tumor clinical trial.A study of first‐line chemotherapy for advanced NSCLC showed that 100 mg/mMost toxicities were manageable with supportive care or appropriate dose reductions, and especially well tolerated in the 70 mg/mThe cost and supply of cancer drug are issues that should be considered in the healthcare system. The trial in our current study is in line with near‐equivalence concept.Our trial had several limitations. First, pharmacokinetics or pharmacodynamics analysis was not conducted. However, pharmacokinetic data for nab‐PTX is similar for Japanese and non‐Japanese patients,In conclusion, both standard dose and low dose of nab‐PTX monotherapy are active for previously treated NSCLC patients with better safety profile. Therefore, nab‐PTX 70 mg/m